Laigo Bio closes €17M seed to advance SureTACs

This article was published on March 27, 2026 The Dutch biotech’s SureTACs platform targets membrane proteins that have long eluded conventional drug discovery by engineering them out of existence rather than blocking them. Biovance Capital joins as new co-lead alongside Kurma Partners in a final close that brings the oversubscribed seed round to €17 million. Most drugs work by blocking proteins. They attach to a target and stop it from doing something harmful. The problem is that this approach only works when the target has a convenient pocket to block, and many of the proteins most implicated in cancer and autoimmune disease do not. They are membrane-bound, structurally awkward, and have been classified as “undruggable” for decades. Laigo Bio, a biotech based in Utrecht, is pursuing a different approach: instead of blocking these proteins, it engineers their destruction. The company has completed the final close of an oversubscribed €17 million seed round, adding €5.5 million in a second close to the €11.5 million it raised in December 2025. Biovance Capital joins as new co-lead investor alongside existing co-lead Kurma Partners. The full syndicate now comprises Kurma Partners, Bi

Mar 27, 2026 → Mar 27, 2026